MannKind Corp. (MNKD)

[jimmac]

Why Sanofi will renew for 2016

They are offering the same worldwide exclusive deal with
Lexicon for their oral diabetic drug.
Thats not approved until mid-late 2016.
( if it gets approved)
Sanofi PR about that offer came out Nov2015

That stock will likely then be hit with short sellers for the same reason MNKD has been.
Many don't want it to succeed cause it rocks the current very profitable diabetic boat.

Sanofi wants this market and is covering all areas.
They don't want to lose world wide Afrezza especially after
Europe/China and everyone else is approved for sales.

What if the Lexicon oral isn't approved/delayed and they
drop Afrezza...then they end up with nothing except their
current losing market share.